Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke by Pizzo, E et al.
2591
Ischemic stroke is the third highest cause of death in the United Kingdom and a leading cause of disability.1 The 
overall incidence is postulated to increase over the next 5 years 
by the WHO.2 The economic burden of stroke is estimated 
at £9 billion per year in the United Kingdom ($38 billion 
in the United States) and is estimated to rise.3,4 Intravenous 
tissue-type plasminogen activator (IV-tPA) for cerebral arterial 
occlusion is the proven therapy for acute ischemic stroke.5,6 
However, new strategies are increasingly involving adjunctive 
endovascular techniques, especially when fibrinolysis is con-
traindicated or has failed.
Recently, 5 randomised controlled trials (Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands [MR 
CLEAN], Endovascular Treatment for Small Core and Proximal 
Occlusion Ischemic Stroke (ESCAPE), Extending the Time for 
Thrombolysis in Emergency Neurological Deficits - Intra-Arterial 
(EXTEND-IA), Solitaire With the Intention for Thrombectomy 
as Primary Endovascular Treatment (SWIFT PRIME) Trial, and 
Endovascular Revascularization With Solitaire Device Versus 
Best Medical Therapy in Anterior Circulation Stroke Within 8 
Hours (REVASCAT)) demonstrated superior benefit of adjunc-
tive mechanical thrombectomy versus IV-tPA alone when there 
is a major vessel occlusion.7–11 This has been propagated by a 
new generation of thrombectomy devices, stent retrievers, which 
demonstrate a higher arterial recanalization rate and a better 
clinical outcome.12–14 More importantly, this is in patients with 
proximal large vessel occlusions who are known through the 
natural history of the disease to have a poor outcome.15
Stent retrievers have consistently shown significantly better 
angiographic, safety, and clinical outcome data than the Merci 
Retriever.16–21 Stent retrievers also seem to produce higher com-
plete recanalization rates than Penumbra, although no head-to-
head trial has been performed.22 A meta-analysis demonstrated 
that early vessel recanalization, using a range of methods, is 
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associated with a 4- to 5-fold increase in the odds of good final 
clinical outcome, with a similar decrease in odds of death.12
Benefit of treatments is usually measured according 
to functional outcome at 3 months. Implementation of new 
treatments also depends on cost and affordability, for which 
a health economic study is usually needed. Stroke itself is an 
expensive disease in terms of its societal, personal, and finan-
cial impact. The rationalization concerning the clinical value 
and effectiveness of thrombectomy is guided by information 
regarding the benefits, risks, and costs associated. It has been 
suggested that although the upfront costs of thrombectomy are 
high, the potential reduction in morbidity can result in savings 
downstream both in the hospital and in the community setting, 
resulting in a significant reduction in the overall economic 
burden from stroke.
Decisions to implement new technologies in the UK 
National Health Service are increasingly being made taking into 
account economic considerations, such as cost-effectiveness 
and budget impact. Previous economic evaluations of throm-
bectomy have been undertaken in the United States and are 
based on single arm studies of a range of mechanical devices, 
now superseded in a rapidly developing field.22–25 Therefore, 
the purpose of this study was to model the cost-effectiveness of 
mechanical thrombectomy in the hyperacute management of 
stroke in the United Kingdom, based on a meta-analysis of the 
data recently published using the 5 randomized control trials, 
which have used predominantly stent retrievers.
Methods
This was a model-based cost-utility analysis, with outcomes mea-
sured in terms of quality adjusted life years (QALYs),26 which are 
the recommended outcomes for economic evaluation in the United 
Kingdom.27 The number of deaths averted is also reported as an ad-
ditional outcome measure.
Model Structure
A short-run decision analytic model (Figure 1A) was created to ana-
lyze data on costs and clinical outcomes within 3 months from stroke 
and subsequently was used to distribute a theoretical cohort of pa-
tients into 1 of 3 possible health states (see Outcomes). A long-run 
Markov state-transition model was then used to estimate the expected 
costs and outcomes over a life-time horizon of 20 years, using cy-
cles of 3 months (Figure 1B). The analysis was undertaken from the 
perspective of the UK National Health Service and Personal Social 
Services. Costs were calculated in 2013–2014 UK pounds and are 
presented in US$ using an exchange rate of £1=US$1.65.28 Where 
appropriate, costs were converted to 2013–2014 prices using National 
Health Service Pay and Prices Indices.29 Outcomes are measured in 
terms of deaths averted and quality adjusted life years (QALYs) 
gained. In the long-run model, all costs and outcomes after the first 
year are discounted at an annual rate of 3.5%.27
Management Strategies
Two treatment options were considered, IV-tPA alone versus me-
chanical thrombectomy and IV-tPA used as a bridging therapy. Only 
data from the recently published randomized controlled trials using 
predominantly stent retrievers were used (see Table I in the online-
only Data Supplement). For both strategies, outcomes were based 
on modified Rankin Scale (mRS) scores measured at 90 days after 
stroke, which were assumed to be affected by recanalization rates 
and symptomatic hemorrhage rates. We assumed that all other as-
pects of inpatient care, including imaging and laboratory studies, 
would be otherwise comparable and consistent with published clini-
cal guidelines.30
Costs
The cost of IV-tPA was estimated to be $2953 (£1214). This includes 
the cost of the medication (assuming an average patient weight of 76 
kg)31,32 and the cost of staff time for the administration29,33 (Table 1). 
Staff costs were estimated using the data on the average cost per hour.29
The cost of the mechanical thrombectomy was estimated to be 
$13 803 (£8365), including the cost of the stent, the materials, and 
the surgery.29,36,37 The cost of the procedure was calculated using a 
microcosting approach, multiplying the average time of an interven-
tion for the hourly cost for each grade of personnel29 (see Table II in 
the online-only Data Supplement).
The costs for the acute management of patients in the first 3 
months after stroke and the following ongoing annual costs were 
taken from a published report.33 Acute and ongoing costs differ ac-
cording to the level of disability, measured by mRS score. Acute costs 
include the length of stay in the Hyper Acute Stroke Unit, in the Acute 
High Dependence Unit, and in the rehabilitation ward, as well as the 
supported discharge cost and community care costs.
The cost of a recurrent stroke has been assessed internally as-
suming the cost is the same in each intervention arm. Because it is 
not possible to predict the type and severity of a recurrent stroke and 
Figure 1. Decision model. A, Short-run analytic model. B, Long-run Markov model structure. IV-tPA indicates intravenous tissue-type 
plasminogen activator; and mRS, modified Rankin Scale.
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Table 1. Model Parameters and Range of Values for Sensitivity Analysis: Utilities Scores, Costs, Probabilities, and Transition 
Probabilities
Base-Case Value
Univariate Sensitivity 
Analysis Distribution Range Alpha-Beta Source
Probabilities
  mRS 0-1-2 after IV-tPA and thrombectomy 0.46 Dirichlet 0–1 291-342 Multiple sources
  mRS 3-4-5 after IV-tPA and thrombectomy 0.39 Dirichlet 0–1 247-386 Multiple sources
  mRS 6 after IV-tPA and thrombectomy 0.15 Dirichlet 0–1 95-538 Multiple sources
  mRS 0-1-2 after IV-tPA alone 0.26 Dirichlet 0–1 169-481 Multiple sources
  mRS 3-4-5 after IV-tPA alone 0.55 Dirichlet 0–1 358-293 Multiple sources
  mRS 6 after IV-tPA alone 0.19 Dirichlet 0–1 124-527 Multiple sources
  If IV-tPA alone
   mRS 0-1-2 after recurrent stroke 0.26 Dirichlet 0–1 260-740 Short-run model
   mRS 3-4-5 after recurrent stroke 0.55 Dirichlet 0–1 550-450 Short-run model
   mRS 6-death after recurrent stroke 0.19 Dirichlet 0–1 190-810 Short-run model
  If mechanical thrombectomy
   mRS 0-1-2 after recurrent stroke 0.46 Dirichlet 0–1 460-540 Short-run model
   mRS 3-4-5 after recurrent stroke 0.39 Dirichlet 0–1 390-610 Short-run model
   mRS 6-death after recurrent stroke 0.15 Dirichlet 0–1 150-850 Short-run model
Transition probabilities
  Movement from up to end of year 1 to 3 months
   Independent mRS 0-1-2
    Independent mRS 0-1-2 0.955 Dirichlet 0–1 1337-63 Ref. 33
    Dependent mRS 3-4-5 0.024 Dirichlet 0–1 34-1366 Ref. 33
    Recurrent stroke 0.013 Dirichlet 0–1 18-1382 Ref. 33
    Dead mRS 6 0.008 Dirichlet 0–1 11-1389 Ref. 33
   Dependent mRS 3-4-5
    Dependent mRS 3-4-5 0.919 Dirichlet 0–1 1287-113 Ref. 33
    Independent mRS 0-1-2 0.029 Dirichlet 0–1 41-1359 Ref. 33
    Recurrent stroke 0.013 Dirichlet 0–1 18-1382 Ref. 33
    Dead mRS 6 0.039 Dirichlet 0–1 55-1345 Ref. 33
  Movement from after year 1 to 3 months
   Independent mRS 0-1-2
    Independent mRS 0-1-2 0.979 Dirichlet 0–1 1371-28 Ref. 33
    Dependent mRS 3-4-5 0.000 Dirichlet 0–1 17-1382 Ref. 33
    Recurrent stroke 0.013 Dirichlet 0–1 11-1388 Ref. 33
    Dead mRS 6 0.008 Dirichlet 0–1 11-1388 Ref. 33
   Dependent mRS 3-4-5
    Dependent mRS 3-4-5 0.948 Dirichlet 0–1 1327-72 Ref. 33
    Independent mRS 0-1-2 0.000 Dirichlet 0–1 17-1382 Ref. 33
    Recurrent stroke 0.013 Dirichlet 0–1 54-1345 Ref. 33
    Dead mRS 6 0.039 Dirichlet 0–1 55-1345 Ref. 33
   Recurrent stroke
    Independent mRS 0-1-2 after IV-tPA alone 0.834 Dirichlet 0–1 834-165 Ref. 33, 34
    Dependent mRS 3-4-5 after IV-tPA alone 0.137 Dirichlet 0–1 136-863 Ref. 33, 34
    Dead mRS 6 after IV-tPA alone 0.029 Dirichlet 0–1 28-971 Ref. 33, 34
    Independent mRS 0-1-2 after IV-tPA and 
thrombectomy
0.867 Dirichlet 0–1 867-132 Ref. 33, 34
    Dependent mRS 3-4-5 after IV-tPA and 
thrombectomy
0.104 Dirichlet 0–1 103-896 Ref. 33, 34
    Dead mRS 6 after IV-tPA and thrombectomy 0.029 Dirichlet 0–1 28-971 Ref. 33, 34
(Continued )
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therefore the correspondent treatment, the cost to treat a recurrent 
stroke is calculated as the mean expected cost to treat an average 
stroke that may not need thrombolysis or thrombectomy.
Outcomes
Patients were categorized into 1 of 3 health outcome states based on 
their predicted mRS scores: independent (mRS score ≤2), dependent 
(mRS score 3–5), or dead (mRS=6).38 We assumed the patient re-
mained in the same health state for the first 3 months. After the initial 
allocation of patients into mRS categories, a Markov model distrib-
uted a theoretical cohort of 1000 patients into the 3 states over time 
and includes the additional health status of a patient having a recur-
rent stroke. The cohort of patients receiving the intervention treat-
ment has been estimated using the national UK data from the stroke 
audit.39 According to the audit, 19 638 patients had a stroke between 
January and March 2014. Only 11.5% were given IV-tPA. We assume 
that patients eligible for thrombectomy are around 80% of those with 
a major occlusion (National Institute of Health Stroke Scale (NIHSS) 
score >16), which means 1800 patients.
QALYs combine length of life and quality of life, the latter being 
measured by utility scores. A utility score of 1 represents full health 
and a score of 0 of death. We used the utility scores from Dorman 
et al,35 the Sandercock et al40 systematic review, and the ScHARR 
report33 for the independent and dependent states because these are 
the most updated and reliable values available that take into account 
the EuroQol elicitation method (Table 1). We used the utility scores 
from Morris et al34 for recurrent strokes (Table 1). Other sources were 
used23,33 for the sensitivity analysis.
Probabilities
The probability of being independent, dependent, or dead in each 
treatment arm were calculated using the data provided from the 5 ran-
domized controlled trials.7–11 We applied the transition probabilities in 
Table 1,23 transformed for cycles of 3 months. In the base-case, the 
transition probability of moving from an independent state to recur-
rent stroke was assumed to be the same as moving from a dependent 
state to recurrent stroke, but this was varied in sensitivity analysis. 
Those who were in the dependent state at 12 months were assumed 
to be unable to move to the independent state thereafter. Those in the 
independent state at 12 months were assumed to remain in that state 
unless they survived another stroke, in which case they could either 
die or move into a dependent state or remain independent.32,40,41
Measuring Cost-Effectiveness
Total QALYs and costs were calculated by multiplying the number of 
patients in each state by the calculated utilities and costs for that state.
Cost-effectiveness was measured in terms of the incremental cost 
per QALY gained and the Net Monetary Benefits (NMB) of throm-
bectomy plus IV-tPA compared with IV-tPA alone. The NMB was 
calculated as the mean QALYs per patient accruing to that treatment 
multiplied by the decision-maker’s maximum willingness to pay for a 
QALY (also referred to as the cost-effectiveness threshold) minus the 
mean cost per patient for the treatment. In the United Kingdom, the 
lower and upper limit of the maximum willingness to pay for a QALY 
are $33 000 (£20 000) and $49 500 (£30 000), respectively.27
Sensitivity Analysis
One-way sensitivity analysis was undertaken, varying the probabilities, 
utilities, and costs, one at a time within the ranges listed in Table 1.
A probabilistic sensitivity analysis was also undertaken to de-
termine the impact of the uncertainty surrounding the model input 
parameters (see Table III in the online-only Data Supplement).27 In 
Table 1, we describe the distribution assigned to each parameter 
value.42 A random value from the corresponding distribution was 
selected. This generated an estimate of the mean cost and mean 
QALY and the NMB associated with each treatment. This was re-
peated 10 000 times, and the results for each simulation were noted. 
The proportion of times either treatment (thrombectomy or IV-tPA) 
had the highest NMB was calculated for a range of values of the 
willingness to pay for a QALY. The results are summarized us-
ing cost-effectiveness acceptability curves in Figure 2. The mean 
cost, QALYs, and NMB for each treatment were calculated from 
the 10 000 simulations; these are probabililistic results (Figure 3; 
online-only Data Supplement).
Results
Using base-case values, mechanical thrombectomy after an 
IV-tPA to treat acute large-vessel ischemic stroke was associated 
with incremental costs of $12 262 (£7431) per patient and a gain 
Utilities
  Independent mRS 0-1-2 0.74 0.7–0.77 Beta 0–1 684-3021 Ref. 35
  Dependent mRS 3-4-5 0.38 0.29–0.47 Beta 0–1 60-590 Ref. 35
  Recurrent stroke 0.34 0.32–0.36 Beta 0–1 540-5685 Ref. 34
  Dead mRS 6 0 0
Costs
  Cost of alteplase IV-tPA $2953.59 Gamma Ref. 29, 31–33
  Cost of thrombectomy $13 803.04 $9677–$17 943 Gamma Ref. 29, 31, 36, 37
  Acute costs first 3 months
   3 months acute costs independent mRS 0-1-2 $11 309.46 Gamma Ref. 29, 33, 36, 37
   3 months acute costs dependent mRS 3-4-5 $24 201.35 Gamma Ref. 29, 33, 36,37
   Cost of acute event fatal stroke mRS 6 $15 547.44 Gamma Ref. 29, 33, 36, 37
  Cost of recurrent stroke $589.20 Gamma Internal model
  Ongoing costs every 3 months
   Independent mRS 0-1-2 $771.88 Gamma Ref. 29, 33, 36, 37
   Dependent mRS 3-4-5 $2074.62 Gamma Ref. 29, 33, 36, 37
IV-tPA indicates intravenous tissue-type plasminogen activator; and mRS, modified Rankin Scale.
Table 1. Continued
Base-Case Value
Univariate Sensitivity 
Analysis Distribution Range Alpha-Beta Source
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of 1.05 QALYs per patient over 20 years (Table 2). The additional 
costs were because of the cost of the device and the cost of the 
procedure. QALYs are higher for mechanical thrombectomy 
because it saves more lives, and those patients who survive are 
more likely to have a better health outcomes and be independent 
(mRS 0,1,2). Assuming a cohort of 1000 patients, the number 
of deaths over 20 years was 787 in patients treated with IV-tPA 
alone and 716 in patients treated with thrombectomy. Therefore, 
the mechanic thrombectomy averted 71 deaths over 20 years.
The incremental cost-effectiveness ratio of mechanical 
thrombectomy compared with IV-tPA was $11 651(£7061) 
per QALY gained. The NMB of thrombectomy plus IV-tPA 
was higher than the NMB of IV-tPA alone at both the 
lower and upper limits of the maximum willingness to pay 
for a QALY, indicating that this option was preferred on 
cost-effectiveness ground. As expected, the probabilistic 
results were similar (see Table III in the online-only Data 
Supplement).
Figure 2. Cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different values of the willingness 
to pay for a quality-adjusted life years (QALY). In the United Kingdom, the lower and upper limit of the maximum willingness to pay for a 
QALY are $33 000 (£20 000) and $49 500 (£30 000) respectively.
Figure 3. Monte Carlo simulations of incremental cost per quality-adjusted life years (QALY) gained of the mechanical thrombectomy on a 
cohort of 1000 patients.
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The results of the 1-way sensitivity analysis showed that 
increasing the cost of thrombectomy by 139% from $13 803 
(£8365) to US $33 000 (£20 000) will make the new inter-
vention borderline cost-effective for the lower value of the 
maximum willingness to pay for QALY. If the utility for the 
independent patients (mRS 0-1-2) were decreased from 0.74 
to 0.34, then the intervention is borderline cost-effective. 
The results were not sensitive to changing the values of any 
of the other parameters included in the univariate sensitivity 
analysis.
The cost-effectiveness acceptability curves for the 2 inter-
ventions show that mechanical thrombectomy had 100% 
probability of being cost-effective at the lower and upper val-
ues of the maximum willingness to pay for QALY commonly 
used in United Kingdom (Figure 2).
Discussion
Our principle finding is that the interventional treatment arm 
consisting of IV-tPA followed by mechanical thrombectomy 
for acute large-vessel ischemic stroke saves 1 life for every 
14 thrombectomies performed, reduces disability, and is cost-
effective when compared with IV-tPA alone.
Although the cost of thrombectomy is higher than that of 
IV-tPA initially, it leads to savings downstream in the stroke 
care pathway because of better outcomes. Between January 
and March 2014, 19 638 new cases of stroke were registered 
in the United Kingdom39; 87.3% were ischemic strokes and 
11.5% had thrombolysis. 15% of ischemic strokes registered 
an acute large vessel stroke with an NIHSS score >16; there-
fore, thrombectomy could potentially be performed in 20% 
of patients who had thrombolysis. This means that in 1 year, 
around 1800 patients could have had a thrombectomy, for an 
incremental cost (budgetary impact) of $22 million (£13.4 
million).
The recent Oxford Vascular study reports that each 
additional point in the NIHSS score can increase total costs 
over 5 years by 15%.43 Therefore, modest improved out-
comes are often cost-effective from a societal perspective. 
These benefits need to be weighed against the procedural 
risks and the increased risk of symptomatic intracerebral 
hemorrhages. Although initially symptomatic hemorrhage 
appeared to be higher among those undergoing throm-
bectomy, subsequent studies have shown similar rates for 
IV-tPA and thrombectomy versus tPA alone as evident in 
Tables III in the online-only Data Supplement. In fact, in 
the studies included in this article, the average hemorrhage 
rates were similar (4.6% for thrombectomy versus 3.8% for 
IV-tPA).
Earlier this year, the first randomized controlled studies, 
MR CLEAN, ESCAPE, EXTEND IA, SWIFT-PRIME, and 
REVASCAT, demonstrate significant benefit with thrombec-
tomy, which was contributed by the higher recanalization 
rate.7–11 Studies to date have shown a correlation between 
recanalization and clinical outcome.12,44 It is likely that the 
development and evolution of mechanical thrombectomy in 
time will lead to better recanalization rates. We expect the cost 
of thrombectomy to decrease over time because of decreas-
ing costs of the intervention and discounts in the device used 
secondary to market competition. This will improve the cost-
effectiveness of the new intervention.
There is no other cost-effectiveness study for thrombec-
tomy performed in the United Kingdom. However, similar 
studies have been done in the United States based on single 
arm studies, which also demonstrated cost-effectiveness of 
$16 001 per QALY gained,23 $12 120 per QALY gained,25 
and $9386 per QALY gained.24 Patil et al focussed on 
patients whom could receive treatment within 8 hours but 
were not eligible for IV-tPA. Nguyen-Huynh et al studied 
patients beyond 3 hours and who were then offered mechan-
ical thrombectomy or antiplatelet therapy and supportive 
care.24 However, Kim et al looked at a similar question 
to ours, that is, the use of IV-tPA as a bridging therapy to 
mechanical thrombectomy versus IV-tPA alone.23 However, 
their data were based on the Multi-MERCI study using 
the Merci retrieval systems (Concentric, s-Hertogenbosch, 
Netherlands), as well as some use of intra-arterial thrombol-
ysis and angioplasty. As mentioned earlier, stent retrievers 
have been shown to be significantly better than the Merci 
retrieval system.16–21 The advantage of this study is that we 
have used data from randomized controlled trials predomi-
nantly using stent retriever devices. Despite several differ-
ences among cost-effectiveness studies, all have concluded 
that mechanical thrombectomy is cost-effective compared 
with medical therapy.
The analysis has several limitations. In the absence of 
data, we have assumed the probability of a recurrent stroke 
is the same irrespective of the level of disability after initial 
stroke, when we might expect the probability of recurrent 
stroke to be higher among the more disabled. The results of 
our sensitivity analysis showed that our conclusions were not 
sensitive to this assumption.
The analysis was undertaken from the perspective of the 
UK National Health Service. A wider perspective, such as a 
societal one, would also include impacts on the rest of society, 
including patients, families, and business. Given that stroke is 
the leading cause of disability in United Kingdom,1 it is likely 
that the cost savings attributable to mechanical thrombectomy 
would be greater than demonstrated if costs from other view-
points were included.
Table 2. Base-Case Results: Expected Values per 1000 
Patients
IV-tPA
Mechanical 
Thrombectomy Difference
Costs $52 494 730 $64 757 281 $12 262 551
Deaths 787 716 −71
QALYs 3790 4842 1052
ICER $11 651
Net monetary benefit
  Lower $72 563 794 $95 031 346
  Upper $135 093 056 $174 925 660
Costs are based on 2013–2014 prices. The point estimates are calculated using 
base-case values of the model parameters (deterministic results). The Net Monetary 
Benefit is calculated at the lower and upper limits of the willingness to pay for a 
QALY, which in the UK are $33 000 (£20 000) and $49 500 (£30 000), respectively. 
ICER indicates Incremental cost-effectiveness ratio; IV-tPA, intravenous tissue-type 
plasminogen activator; and QALY, quality-adjusted life years.
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Summary
We have demonstrated in this first cost-effectiveness study that 
the use of predominantly stent retrievers in mechanical throm-
bectomy after IV-tPA is cost-effective in the United Kingdom, 
based on current data. However, we hope that this study will 
supplement the recently published randomized controlled tri-
als together with evidence demonstrating an increasing preva-
lence of stroke among young adults45,46 to assist healthcare 
commissioners regarding purchasing and investing in this new 
aspect of acute stroke services.
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SUPPLEMENTAL MATERIAL 
Table I: Summary of mRS outcomes from five randomised control trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trial: 
Intervention 
group mRS 0-2 mRS 3-5 mRS 6 Total 
 
Haemorrhage 
rate (%) 
 
References 
MR CLEAN Thrombectomy 76 108 49 233 7.7 7 
 
tPA 51 157 59 267 6.4 7 
ESCAPE Thrombectomy 87 60 17 164 3.6 8 
 
tPA 43 76 28 147 2.7 8 
EXTEND 1A Thrombectomy 25 7 3 35 0 9 
 
tPA 14 14 7 35 6 9 
SWIFT-PRIME Thrombectomy 59 30 9 98 0 10 
 
tPA 33 53 12 98 3 10 
REVASCAT Thrombectomy 45 39 19 103 4.9 11 
 
tPA 29 58 16 103 1.9 11 
      
  
Total number 
of Thrombectomy 292 244 97 633 
 
29 
 
patients tPA 170 358 122 650 25  
      
  
mean figures Thrombectomy 46% 39% 15% 100% 4.6  
 
tPA 26% 55% 19% 100% 3.8  
Table II: Detailed breakdown costs for iv TPA and iv Thrombectomy 
Cost of IV-tPA Cost (US $ 2014) Reference 
Cost of Alteplase 
 $                               
950.40  31 
Staff time     
5 min additional nurse time       14.01  29,33 
190 min registrar time     378.02  29,33 
50 min consultant time     194.76  29,33 
5 min routine observation by senior nurse          2.66  29,33 
12 additional set of observation at 5 min    
each     233.71  29,33 
5 hours 1:1 Senior nurse care  1,168.54  29,33 
10 min overnight senior nurse care       11.49  29,33 
Total cost of administration  2,003.19    
Total cost IV-tPA  2,953.59    
      
Cost of Thrombectomy Cost (US $ 2014) 
 
Reference 
 
Cost of material     
device    7,566.08   36-37  
guidecatheter        159.73   36-37 
guidewire        168.14   36-37 
microcatheter        672.54   36-37 
stent thrombectomy     3,154.21   36-37 
aspiration catheter        840.68   36-37 
Total cost of material  12,561.37    
 
 
     
Cost of surgery 
surgery staff Cost (US $ 2014) Reference 
surgeon 
                                    
411.93   29, 36-37  
radiographer      108.87   29, 36-37 
instrument nurse        64.73   29, 36-37 
circulating nurse        61.79   29, 36-37 
circulating nurse        61.79   29, 36-37 
anaesthesist      411.93   29, 36-37 
anaesthetic nurse      120.64   29, 36-37 
Total cost of surgery   1,241.68    
Total cost of Thrombectomy 
                         
13,803.04    
    
 
 
 
 
 
 
 
 
 Table III: Probabilistic sensitivity analysis results: Expected values per 1,000 patients. Costs are based on 2013-14 prices The Net Monetary Benefit is 
calculated at the lower and upper limits of the willingness to pay for a QALY, which in the UK are $33,000 (£20,000) and $49,500 (£30,000) respectively.  
  IV-tPA  M. Thrombectomy Difference 
Costs 
(95% CI) 
$ 52,849,215 
($ 51,073,057- $ 53,837,494) 
$ 64,887,437 
($ 63,546,387 - $ 65,957,721) 
$ 12,038,222 
($ 10,462,678 -$ 14,155,764) 
QALYs 
(95% CI) 
3,723 
(3,590-3,988) 
4,677 
(4,617-5,068) 
954 
(753-1352) 
ICER 
(95% CI)     
$ 12,614 
($9,043 - $15,988) 
Net Monetary Benefit        
Lower   $                       70,002,953   $                89,457,959    
Upper  $                     131,429,037   $              166,630,656    
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